FYB201 (Ranibizumab)
Retinal diseases (e.g., nAMD)
ApprovedActive
Key Facts
About Formycon
Formycon is a German, publicly traded biosimilar developer with a commercial-stage product and a robust pipeline targeting high-value biologic drugs. The company leverages deep scientific and regulatory expertise to develop biosimilars for markets like the EU and US, aiming to capture significant value in the growing biosimilars market. Its strategy focuses on complex molecules in ophthalmology and immunology, with recent progress including a key settlement for its aflibercept biosimilar in Europe.
View full company profileTherapeutic Areas
Other Retinal diseases (e.g., nAMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| FYB203 (Aflibercept) | Formycon | Phase 3/Registration |